What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?

Acta Ophthalmologica

Volumn 91, Issue 2, 2013, Pages

  Spandau, Ulrich ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

AGE DISTRIBUTION; DOSE CALCULATION; DRUG DOSE COMPARISON; EYE AXIS LENGTH; EYE DISEASE; FUNCTIONAL STATUS; GESTATIONAL AGE; HUMAN; LETTER; LOW DRUG DOSE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROLENTAL FIBROPLASIA; SYSTEMIC DISEASE; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AXIAL LENGTH, EYE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84874273691     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2012.02552.x     Document Type: Letter

References (6)

1. Ehlers N, Mathiesen ME, &, Andersen H, (1968): The prenatal growth of the human eye. Acta Ophthalmol (Kbh) 46: 329-349.
2. Harder BC, Baltz SV, Jonas JB, &, Schlichtenbrede FC, (2011): Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther 27: 623-627.
3. Larsen JS, (1971): The sagittal growth of the eye. Acta Ophthalmol 49: 441-444.
4. Lorenz B, (2011): Kommentar: anti-VEGF-Einsatz gut abwägen. Klin Monbl Augenheilkd 225: 488-490.
5. Mintz-Hittner HA, Kennedy KA, Chuang AZ, & BEAT-ROP Cooperative Group (2011): Efficacy of intravitreal bevacizumab for syage 3+ retinopathy of prematurity. N Engl J Med 364: 603-615.
6. Spandau U, Tomic Z, Ewald U, Akerblom H, Larsson E, &, Holmström G, (2012). Time to consider a new treatment protocol for Aggressive Posterior ROP? Acta Ophthalmol [Epub ahead of print].